Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
11/13/2014 > 180 patent applications in 136 patent subcategories.

20140336104 - Acth prophylactic treatment of renal disorders: Provided herein are methods for prophylactic treatment of renal disorders comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual suspected of having, predisposed to, or at risk of developing a renal disorder... Agent:

20140336105 - Anti-inflammatory peptides and use thereof: Anti-inflammatory peptides and pharmaceutical compositions including lysine, alanine, leucine and/or valine for treating inflammatory conditions and uses thereof. Anti-inflammatory peptides for treating IgE-mediated allergies and inflammatory conditions caused by a microbial infection including but not limited to sepsis.... Agent:

20140336108 - Compounds as tyrosine kinase modulators: The present invention is directed to novel compounds of Formula I. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors.... Agent:

20140336107 - Glp-1 receptor agonist peptide gastrin conjugates: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.... Agent:

20140336106 - Tripeptide epoxy ketone protease inhibitors: e

20140336109 - Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin: A method and a composition for decreasing ghrelin levels and/or decreasing ghrelin/unacylated ghrelin ratio in a subject, the method comprising administering an effective amount of unacylated ghrelin, a fragment thereof, an analog thereof and/or pharmaceutically acceptable salts thereof to the subject wherein a reduction in ghrelin levels and/or a reduction... Agent: Alize Pharma Sas

20140336110 - Modified mini-hepcidin peptides and methods of using thereof: Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.... Agent: The Regents Of The University Of California

20140336111 - Therapeutic use of activators of zinc finger protein gl13: The present invention relates to the therapeutic use of activators of the zinc finger protein GLI3 in diseases that are associated with reduced Hedgehog signaling in hepatocytes, in particular Polycystic ovary syndrome, Steatosis hepatis, Steatohepatit is and/or Adipositas. The invention further relates to methods of treating an individual with said... Agent: Universtit&#xe4 T Leipzig

20140336112 - Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other... Agent: Rani Therapeutics, LLC

20140336113 - Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome: The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a... Agent: Vanderbilt University

20140336114 - Buffers for controlling the ph of bone morphogenetic proteins: The present invention provides formulations of cysteine knot proteins, including TGF-β superfamily proteins and bone morphogenic proteins that are pH stabilized. In particular, the present invention relates to the observation that certain buffers enhance the stability of cysteine knot proteins, including TGF-β superfamily proteins and bone morphogenic proteins. In particular,... Agent: Stryker Corporation

20140336115 - Compounds, compositions and methods for the treatment of diseases through inhibiting tgf-ß activity: The present disclosure relates to compounds, compositions and methods for the treatment of diseases through inhibiting the activity of the transforming growth factor beta (TGF-β). More specifically, the disclosed compounds, compositions and methods are useful in the treatment of certain cancers (e.g. multiple myeloma, hematologic malignancies), diseases associated with excessive... Agent: The Uab Research Foundation

20140336116 - Glycosylated polypeptide and drug composition containing said polypeptide: [Problem] To provide a glycosylated polypeptide having an affinity to somatostatin receptors, and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least one amino acid in a somatostatin or an analog thereof being replaced with a glycosylated amino acid.... Agent: Glytech, Inc.

20140336117 - Modified receptor fusion proteins: We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone related diseases that would benefit from growth hormone agonists or antagonists.... Agent: Asterion Limited

20140336118 - Polypeptide for the protection against heart ischemia-reperfusion injury: A peptide of the formula R1-NH-HAEGTFTSDVSSYLEGQAAKEFIAWLVK-CONR2R3 wherein R=H or an organic compound comprising from 1 to 10 carbon atoms and R2 R3=independently H or an alkyl group of 1 to 4 carbon atoms; or certain analogues of said GLP-1 peptide can be used for the treatment and prophylaxis of heart... Agent:

20140336119 - Polypeptides targeting glycosylated muc2 proteins, methods of synthesis, their nucleic acids and uses thereof: The invention relates to polypeptides, defined through a consensus sequence, having a length from 10 to 80 amino-acid residues, and whose polypeptidic sequence comprises or consists of the consensus sequence P1(Xa)P3(Xb)P5(Xc)P6(Xd)P7 (SEQ ID NO: 1), presenting specific patterns. The polypeptides of the invention target glycosylated Muc2 proteins. The invention also... Agent: Institut Pasteur

20140336120 - Compositions and method for treatment of ischemic neuronal reperfusion injury: A method and composition for the treatment of ischemic neuronal reperfusion injury are provided. The composition can include a compound which is a combination of dantrolene and a residue of FMOC-valine. This composition can be used to provide a faster and higher CNS penetration than heretofore experienced with dantrolene. In... Agent: Howard University

20140336121 - Factor h for treatment of rheumatoid arthritis: The present invention provides a method for preventing or inhibiting allograft rejection by a recipient of that allograft by treating the recipient with a composition comprising Factor H (FH). The invention also encompasses methods in which the recipient is also administered one or more immunosuppressants in addition to the Factor... Agent: Baxter International Inc.

20140336122 - Removal of serine proteases by treatment with finely divided silicon dioxide: The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized... Agent:

20140336123 - Beta-arrestin effectors and compositions and methods of use thereof: This application describes a family of compounds acting as β-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.... Agent:

20140336124 - Compositions for regenerating defective or absent myocardium: Injectable collagen based graft compositions and grafts formed from the compositions for tissue regeneration. The compositions and grafts further include a glycosaminoglycan (GAG) to control matrix formation and remodeling.... Agent:

20140336125 - Methods for improving the bioactivity characteristics of a surface and objects with surfaces improved thereby: A method for improving bioactivity and/or biodegradation time of a collagen surgical implant and collagen surgical implants having such improved properties. A gas-cluster ion-beam (GCIB) is formed in a reduced-pressure chamber, a collagen surgical implant is introduced into the reduced-pressure chamber, and at least a first portion of the surface... Agent:

20140336126 - Optineurin-derived polypeptides, their nucleic acids and uses thereof: The invention relates to Optineurin-derived polypeptide(s) consisting of a polypeptidic sequence disclosed in SEQ ID no2, which represents the portion of the wild-type human Optineurin protein sequence from its amino-acid residue 131 to its amino-acid residue 297, or having a polypeptidic sequence encompassing the polypeptidic sequence disclosed in SEQ ID... Agent:

20140336127 - Stabilized peptide helices for inhibiting dimerization of chemokine c motif receptor 2 (ccr2): Peptide helices stabilized by backbone cyclization which are capable of inhibiting dimerization of the Chemokine (C-C motif) receptor 2 (CCR2), as well as pharmaceutical compositions including such backbone cyclized peptide helices. Use of pharmaceutical compositions and peptide helices in treatment of Multiple Sclerosis (MS) and other diseases associated with CCR2... Agent:

20140336128 - Gigaxonin fusion protein and methods for treating giant axonal neuropathy: The present disclosure relates generally to fusion proteins including gigaxonin coupled to a cell penetrant peptide. These fusion proteins can be used to treat GAN in a subject in need thereof. Administration of the fusion proteins allows for control of at least one of Galectin-1 (GAL-1) levels and phosphorylated vimentin... Agent: Indiana University Research And Technology Corporation

20140336129 - Targeting the egfr-sglt1 interaction for cancer therapy: A compound can destabilize a binding interaction between an epidermal growth factor receptor (EGFR) and a sodium/glucose co-transporter 1 (SGLT 1). In one embodiment, the compound is a peptide derived from the interacting domain of EGFR. In another embodiment, the peptide is administered to a patient to treat cancer.... Agent: The University Of Houston System

20140336130 - Targeting en2, pax2, and/or defb1 for treatment of prostate conditions: The present invention relates to the compositions and use of compositions for treating a prostate condition in a subject. The use of composition comprises administering to the subject a subject effective amount of a pharmaceutical composition having a first agent that inhibits EN2 expression and/or EN2 activity and a second... Agent: Phigenix, Inc.

20140336131 - Methods for treating inflammation, autoimmune disorders and pain: Disclosed herein are methods of treating, reducing, or preventing a disease such as oral mucositis, gastric mucositis, or inflammatory fibrosis, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising... Agent: Brigham Young University

20140336132 - Romidepsin solid forms and uses thereof: The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I.... Agent:

20140336133 - Methods and compositions for treating huntington's disease: Disclosed herein are methods and compositions for treating or preventing Huntington's Disease.... Agent:

20140336134 - Iap bir domain binding compounds: s

20140336136 - Carboxylated stilbenes for activating ampk and sirtuins: The present invention relates to the use of certain stilbene derivatives for cosmetic and dermatological applications, in particular prevention and/or treatment of skin aging, as well as to cosmetic and dermatological compositions containing such stilbene derivatives.... Agent: Rahn Ag

20140336137 - Novel nitroso compounds as nitroxyl donors and methods of use thereof: The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl... Agent:

20140336135 - Novel use of rhododendrin: The present invention relates to a novel use of rhododendrin, and more particularly to a composition for antioxidant purposes or for the prevention or treatment of hyperproliferative skin disorders, which comprises rhododendrin as an active ingredient; and a method for inhibiting reactive oxygen species or for preventing and treating a... Agent: Catholic University Industry Academy Cooperation Foundation

20140336138 - Compositions and methods for screening and treatment of sturge-weber syndrome, klippel-trenaunay-weber syndrome, and port-wine stains (pwss): Compositions and methods for treatment of Sturge-Weber Syndrome, Klippel-Trenaunay-Weber Syndrome, Port-Wine Stains and related neurocutaneous disorders are provided. Cell lines having the somatic mutation GNAQ p.Arg183Gln amino acid substitution, which was found to be the cause of port-wine stains (prevalence 1 in 300) and Sturge-Weber syndrome are also provided. Compositions... Agent: Kennedy Krieger Institute, Inc.

20140336139 - Topical application of ivermectin for the treatment of dermatological conditions/afflictions: Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective... Agent:

20140336140 - Methods for providing sialylated oligosaccharides: The invention relates to a method for providing analogs of human milk oligosaccharides (HMO), in particular oligosaccharides containing terminal sialic acid. The method comprises the steps of: a) providing a source of non-digestible galactooligosaccharides (GOS) containing at least two terminally bonded β-linked galactose residues; b) providing a sialic acid donor... Agent:

20140336238 - Antisense oligonucleotides for the treatment of leber congenital amaurosis: The present invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Leber congenital amaurosis.... Agent: Stichting Katholieke Universiteit

20140336239 - Compositions and methods for modulating myeloid derived suppressor cells: Provided are methods and compositions for modulating the differentiation of a myeloid derived suppressor cell (MDSC). In particular, described herein are miR-142 polynucleotides and miR-223 polynucleotides that can be used to modulate differentiation of MDSCs. Increased differentiation of a MDSC population, or cells within an MDSC population, can be achieved... Agent: University Of South Florida (a Florida Non-profit Corporation)

20140336241 - Compositions and methods for prognosis and treatment of prostate cancer: Described herein are compositions and methods for prognosis and treatment of prostate cancer patients. Specifically the invention relates to microRNA molecules associated with the prognosis of prostate cancer, as well as various nucleic acid molecules relating thereto or derived therefrom.... Agent: Rosetta Genomics Ltd.

20140336243 - Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes: This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, methods of using the compositions to inhibit the expression of the Eg5/KSP and VEGF, and methods of using the compositions to treat pathological processes mediated by Eg5/KSP and VEGF expression, such as cancer.... Agent:

20140336240 - Method of treating hyperlipidemia and atherosclerosis with mir-30c: This disclosure provides a novel role for microRNA (miR) regulation of lipid metabolism via the MTP pathway, leading to reductions in apoB secretion and blood lipid levels. MiR regulation of the MTP pathway is shown herein to reduce hyperlipidemia and atherosclerosis in vivo. Therefore, inhibition of MTP expression and activity... Agent: The Research Foundation For The State University Of New York

20140336242 - Micro-rna scaffolds and non-naturally occurring micro-rnas: The present disclosure provides a non-naturally occurring miRNA having a stem-loop structure comprising a scaffold derived from a first endogenous miRNA (e.g., miR-196a-2 or miR-204), a mature strand derived from a second endogenous miRNA, and a star strand sequence that is at least partially complementary to the mature strand sequence.... Agent:

20140336237 - Modulation of signal transducer and activator of transcription 3 (stat3) expression: Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.... Agent:

20140336236 - Novel alk and ntrk1 fusion molecules and uses thereof: Novel ALK and NTRK1 fusion molecules and uses are disclosed.... Agent: Foundation Medicine, Inc.

20140336244 - Methods and products for reawakening retrocyclins: Products and methods are provided for the restoring the endogenous expression of theta-defensins, such as retrocyclin-1, in mamallian cells. The present invention also includes products and methods for inhibiting sexually transmitted virus entry, e.g., HIV-1 virus entry, into a mammalian cell via, for example, administering to a subject an amount... Agent: University Of Central Florida Research Foundation, Inc.

20140336245 - Virus vectors for highly efficient transgene delivery: The invention provides viral vector formulations and methods of uses thereof for delivery of transgenes or therapeutic nucleic acids to human subjects. The formulations include a vector and suitable amounts of empty capsids, viral genome-containing capsids, or viral capsid proteins which are optionally chemically or structurally modified and which bind... Agent:

20140336141 - Mao-b inhibitors derived from the one-carbon cycle: The invention exploits the elucidation of a connection between the S-adenosylmethionine one-carbon cycle and MAO-B levels and describes drug efficacy testing methods and the use of compounds of the S-adenosylmethionine one-carbon cycle as MAO-B inhibitors in disease prevention and treatment.... Agent:

20140336142 - Method for treatment of macular degeneration by modulating p2y12 or p2x7 receptors: Provided is a method of treating or preventing age-related macular degeneration (AMD) in a patient subject to, or symptomatic of the disease, wherein the method comprises restoring normal lysosomal pH (pHL), or acidifying an abnormally elevated pHL, thus decreasing or preventing a damaging accumulation of lipofuscin or waste products in... Agent:

20140336143 - Treatment of ebv and khsv infection and associated abnormal cellular proliferation: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or... Agent: Emory University

20140336145 - Compositions and methods for treating oculopharyngeal muscular dystrophy: The present invention provides intravenous compositions of trehalose for the treatment of signs and symptoms of oculopharyngeal muscular dystrophy (OPMD).... Agent:

20140336144 - External preparation containing nsaids and method for producing the external preparation: Disclosed is an external preparation containing nonsteroidal anti-inflammatory drugs (NSAIDs), which is suppressed in cytotoxicity induced by the NSAIDs. Also disclosed is a method for producing the external preparation. The present invention is based on the finding that skin disorders induced by nonsteroidal anti-inflammatory drugs (NSAIDs) can be suppressed when... Agent:

20140336146 - Novel galectoside inhibitors of galectins: The present invention relates to novel compounds prepared from readily accessible 3-O-propargyl-D-galactopyranoside derivatives and having an effect as i.a., galectin inhibitors, the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to ligands... Agent: Galecto Biotech Ab

20140336148 - Combinations of diacerein and non-steroidal inflammation drugs: The present invention relates to novel pharmaceutical combinations with synergistic action of diacerein or a pharmaceutically acceptable salt of diacerein and non-steroidal inflammatory drugs, having analgesic, anti-inflammatory, antipyretic, and osteoarthritis-treating activities.... Agent:

20140336147 - Hemostatic agents and methods of use: Modified chitosan hemostatic agents include reverse micelles (10) having an outer hydrophobic shell (12) of suitable biocompatible hydrophobic components such as alkanes, and hydrophilic positively charged chitosan moieties (14) enclosed within the hydrophobic shell (12). The hydrophobic shell (12) may be formed by attaching hydrophobic moieties to one end of... Agent:

20140336149 - Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process: A docetaxel inclusion complex having improved water-solubility (up to 5 mg/ml) and stability (stability constant Ka=2056M−1-13051M−1), comprises docetaxel and hydroxypropyl-beta-cyclodextrin and/or sulfobutyl-beta-cyclodextrin in a ratio of 1:10-150. The method includes steps as follows: docetaxel dissolved in ethanol is added into water solution of cyclodextrin via stirring, until docetaxel is completely... Agent:

20140336150 - Administration of karenitecin for the treatment of platinum and/or taxane chemotherapy-resistant or -refractory advanced ovarian cancer: The present invention discloses and claims methods and compositions for the treatment of subjects having advanced ovarian cancer, including platinum and/or taxane chemotherapy resistant or refractory sub-populations, with the administration to the subject having advanced ovarian cancer of the silicon-containing highly lipophilic camptothecin derivative (HLCD), Karenitecin (also known as BNP1350;... Agent: Bionumerik Pharmaceuticals, Inc.

20140336152 - Composition for wet wipes that enhances the efficacy of cleansing while being gentle to the skin: The present invention describes an oil-in-water emulsion composition for wet-wipes delivering an improved body cleansing performance while providing a gentle and smooth feeling to the user.... Agent:

20140336151 - Silicon-containing fumaric acid esters: The present invention is directed to silicon-containing fumaric acid esters of the Formulae I-IV. The silicon-containing fumaric acid esters of Formulae I-IV are useful in transplantation medicine and for the treatment of autoimmune diseases and autoimmune-related diseases. (I), (II), (III) & (IV)... Agent:

20140336154 - Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use: Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using... Agent:

20140336153 - Substituted pyridine derivatives as fabi inhibitors: The present invention provides substituted pyridine derivatives of formula (I), which may be therapeutically useful as as anti-bacterial agents, more particularly FabI inhibitors. Formula (I) in which R1 to R5 and L have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment... Agent:

20140336155 - Active substance combination based on trifluorobutinyl compounds and exhibiting nematicidal and insecticidal properties: The invention relates to novel active substance combinations consisting of heterocyclic trifluorobutenylen of formula (1), wherein X is halogen and n is 0, 1 or 2, and of known insecticide substances. Said novel active substance combinations are suitable for fighting harmful pests like insects and nematodes.... Agent:

20140336156 - Antibodies to 25-hydroxyvitamin d2 and d3 and uses thereof: Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic... Agent:

20140336157 - Methods and compositions for treating cancer: Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17α-hydroxylase/C17,20-lyase inhibitor, such as abiraterone acetate (i.e., 3β-acetoxy-17-(3-pyridyl)androsta-5,16-diene), in combination with at least one additional therapeutic agent such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising a... Agent:

20140336159 - Methods for treating and diagnosing respiratory tract infections: Described are methods of preventing, treating and diagnosing of a subject having a condition, such as, an inflammation or infection of the respiratory tract. Methods of treatment and prevention include administration of effective amounts of calcium salt formulations to a subject. Methods of diagnosing include the use of biomarkers and... Agent:

20140336158 - Nk1 antagonists: wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough.... Agent:

20140336162 - Locally administrated low doses of corticosteroids: This invention provides for using a locally delivered low dose of a corticosteroid to treat pain caused by any inflammatory disease including sciatica, herniated disc, stenosis, mylopathy, low back pain, facet pain, osteoarthritis, rheumatoid arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low... Agent:

20140336160 - Novel glucocorticold receptor agonists: i

20140336161 - Pharmaceutical formulations containing corticosteroids for topical administration: The potency of a topical corticosteroid in a pharmaceutical formulation is maintained even when the concentration of the corticosteroid is substantially reduced by providing the corticosteroid in a formulation containing a liquid oil component that includes a dicarboxylic acid ester and/or a monocarboxylic acid ester.... Agent:

20140336163 - Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug: The invention relates to injectable pharmaceutical compositions, methods of use and formulation, wherein the compositions comprise: one or more water soluble complexes, each complex comprising a cyclodextrin or a cyclodextrin derivative and a hydrophobic drug; at least one preservative; and at least one co-solvent. The compositions are effectively preserved in... Agent:

20140336164 - Biodegradable non-ophthalmic implants and related methods: Biodegradable non-ophthalmic implants include one or more agents dispersed within a biodegradable polymer component. The implants release the agents from the biodegradable polymer component to a target site of a patient as the implant degrades. The agents provided in the implants can be therapeutic agents or diagnostic agents and are... Agent:

20140336166 - Novel purine derivatives and their use in the treatment of disease: The invention relates to PI3K inhibitors of the formula (I) • in which all of the variables are as defined in the specification, to their preparation, to their medical use, in particular to their use in the treatment of cancer and neurodegenerative disorders, and to medicaments comprising them.... Agent: Novartis Ag

20140336171 - Azaindoles useful as inhibitors of janus kinases: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.... Agent:

20140336173 - Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors: This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives of formula (I) wherein R1 is hydrogen, chloro, methyl or methoxy, R2 is hydrogen or methoxy, with the proviso that at least one of R1 and R2 is other than hydrogen, G1 represents chloro, (C1-C4)-alkyl, (C1-C4)-alkoxycarbonyl, 5-membered aza-heteroaryl, or the group —CH2—OR3,... Agent:

20140336169 - Imidazopyrazine syk inhibitors: Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or... Agent: Gilead Connecticut, Inc.

20140336170 - Indazole compounds useful as ketohexokinase inhibitors: The present invention is directed to substituted indazole compounds, pharmaceutical compositions of these compounds and methods of use thereof. The compounds of the present invention are ketohexokinase (KHK) inhibitors, useful for treating or ameliorating a KHK mediated metabolic disorders and/or diseases such as obesity, Type II diabetes mellitus and Metabolic... Agent: Janssen Pharmaceutica Nv

20140336167 - Nampt inhibitors: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.... Agent: Abbvie Inc.

20140336168 - Nampt inhibitors: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.... Agent:

20140336172 - Novel 2h-indazoles as ep2 receptor antagonists: The present invention relates to novel 2H-indazoles of the general formula (I), methods for the preparation thereof and the use thereof for the production of pharmaceutical agents for the treatment of diseases and indications which are linked with the EP2-receptor.... Agent:

20140336174 - Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease: A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject comprises administering to the subject an effective amount of a glucosylceramide synthase inhibitor.... Agent: Genzyme Corporation

20140336165 - Dihydroxy aromatic heterocyclic compound: The present inventors have studied a compound that inhibits DAAO, and confirm that a dihydroxy aromatic heterocyclic compound has a DAAO inhibitory action, and completed the present invention. That is, the dihydroxy aromatic heterocyclic compound of the present invention has a good DAAO inhibitory action, and can be used as... Agent:

20140336176 - Heteroaromatic compounds and their use as dopamine d1 ligands: and pharmaceutically acceptable salts thereof and N-oxides of the foregoing; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, salts or N-oxides, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g.,... Agent: Pfizer Inc.

20140336175 - Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases: wherein R1 is C1-6alkylamino, C1-6alkoxy, or C3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various... Agent: Glaxosmithkline LLC

20140336177 - Inhibitors of the renal outer medullary potassium channel: and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds act as diuretics and natriuretics and are valuable pharmaceutically active compounds for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension and conditions resulting from excessive salt and water retention.... Agent:

20140336178 - Compositions and methods for modulating interaction between polypeptides: The present invention is based, in part, on assays we conducted that revealed compounds that may be used to treat or prevent diseases characterized by an abnormal or undesirable association of one protein with another.... Agent: Massachusetts Institute Of Technology

20140336179 - Acetone solvate of ivabradine hydrochloride: The present invention relates to a novel solvate of ivabradine hydrochloride, a process of its preparation and its use for the preparation of specific polymorphic forms of ivabradine hydrochloride.... Agent: Sandoz Ag

20140336180 - Combination of mek inhibitors and selective inhibitors of aurora a kinase: The present invention relates to methods for the treatment of proliferative disorders. In particular, the invention provides methods for treatment of proliferative disorders by administering a MEK inhibitor in combination with a selective inhibitor of Aurora A kinase.... Agent: Millennium Pharmaceuticals, Inc.

20140336181 - Use of polymorphisms for identifying individuals at risk of developing autism: The present invention relates to nucleic-acid based diagnostics and the use of such diagnostics for the diagnosis of developmental disorders. Novel methods of assessing individuals for the risk of developing autism through the identification of mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene alone or in combination with... Agent:

20140336182 - Aurora kinase modulators and method of use: wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase... Agent:

20140336183 - Compositions and method for treatment of ischemic neuronal reperfusion injury: A method and composition for the treatment of ischemic neuronal reperfusion injury are provided. The composition may include at least a benzodiazepine class material. In another form, the composition may include at least two components selected from the group consisting of an antagonist of the type 3 ryanodine receptor, an... Agent:

20140336184 - Method to enhance cognition: The present invention concerns methods and compositions regarding suppression of double stranded RNA-activated protein kinase (PKR) to enhance cognition in an individual. In specific cases, an inhibitor of PKR is provided to the individual such that cognition is enhanced thereby, including by enhancing memory, for example. Kits are encompassed in... Agent:

20140336185 - Novel glp-1 receptor stabilizers and modulators: Compounds that bind the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, methods of their therapeutic and/or prophylactic use, and methods of their use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor are provided. Certain compounds may have activity as modulators or potentiators with respect... Agent:

20140336186 - Heterocyclic compounds as pesticides: The present application relates to the use of heterocyclic compounds, some of which are known, for controlling animal pests, including arthropods and in particular insects, furthermore to novel heterocyclic compounds and to processes for their preparation.... Agent:

20140336187 - Methods for treating leishmaniasis: Methods are provided to inhibit proliferation of Leishmania parasites, and in particular Leshmania donovani with imido-substituted 1,4-naphthoquinones, including novel compounds. Administering an imido-substituted 1,4-naphthoquinone can used to provide prophylaxis or treatment to a patient in need of treatment against leishmaniasis disease.... Agent:

20140336188 - N-substituted indenoisoquinolines and syntheses thereof: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.... Agent: The Government Of The United States Of America As Represented By The Secretsr

20140336189 - 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof: S

20140336190 - Benzimidazole derivatives as bromodomain inhibitors:

20140336192 - 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors: There are provided substituted 3-phenyl-isoquinolin-1(2H)-one derivatives which selectively inhibit the activity of poly(ADP-ribose) polymerase PARP-1 with respect to poly(ADP-ribose) polymerase PARP-2. The compounds of the present invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention... Agent: Nerviano Medical Sciences S.r.l. A Corporation

20140336191 - Quinolinyloxyphenylsulfonamides: The present invention relates to quinolinyloxyphenylsulfonamides and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these quinolinyloxyphenylsulfonamide compounds as well as pharmaceutical compositions containing at least one of these compounds together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said quinolinyloxyphenylsulfonamides are useful for prophylaxsis, treatment and/or... Agent:

20140336193 - Potent non-urea inhibitors of soluble epoxide hydrolase: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or... Agent:

20140336194 - Method of treating contrast-induced nephropathy: e

20140336195 - Aryloxmethyl cyclopropane derivatives as pde10 inhibitors: The present invention is directed to aryloxymethyl cyclopropane derivatives which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or... Agent:

20140336196 - Phosphoric acid salts of sitagliptin: The present invention relates to novel phosphoric acid salts of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine, and polymorphs, hydrates and solvates thereof, which are potent inhibitors of dipeptidyl peptidase-IV useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as type 2 diabetes. The present invention also relates to the process... Agent: Merck Sharp & Dohme Corp.

20140336197 - Substituted imidazo [1,5-a]quinoxalines as a pde9 inhibitor: e

20140336198 - Amine derivatives as potassium channel blockers: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis,... Agent: Bionomics Limited

20140336199 - Compounds and pharmaceutical compositions for treating disorders associated with the 5-ht1a and 5-ht2a receptors: which are pharmacologicaly active and able to act on the 5-HT1A and 5-HT2A serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their... Agent: Ache International (bvi) Ltd.

20140336200 - Arylosulfonamides for the treatment of cns diseases: Arylsulphonamide derivatives of formula (I) and pharmaceutically acceptable salts thereof. The compounds may be useful for the treatment and/or prevention of disorders of the central nervous system.... Agent: Adamed Sp. Z O.o.

20140336201 - Bipyridyl derivatives: The present invention relates to novel bipyridyl derivatives of formula (I) and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such... Agent:

20140336202 - Methods of identifying and using mdm2 inhibitors: Methods of treating subjects with cancer and screening for MDM2 inhibitors that may be effective cancer therapeutics are provided herein. The cancers that may be treated using MDM2 inhibitors using the methods described herein include those that are or may become resistant to treatment with tyrosine kinase inhibitors. Methods of... Agent: Duke University

20140336203 - Crystalline forms of a bruton's tyrosine kinase inhibitor: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of... Agent:

20140336206 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are pyrazolo[3,4-d]pyrimidines that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent:

20140336204 - Methods of inhibiting xanthine oxidase activity in a cell: Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.... Agent:

20140336205 - Small molecule xanthine oxidase inhibitors and methods of use: Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.... Agent:

20140336207 - Pyrrole six-membered heteroaryl ring derivative, preparation method thereof, and medicinal uses thereof: The present invention relates to a pyrrole six-membered heteroaryl ring derivative, the preparation method therefor, and the medicinal uses thereof. Specifically, the present invention relates to a new pyrrole six-membered herteroaryl ring derivative as represented by formula (I), the preparation method therefor, a medicinal composition comprising the derivative, and a... Agent:

20140336208 - 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds: e

20140336210 - Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers: This invention relates to aryl urea compounds in combination with cytotoxic or cytostatic agents for use in treating raf kinase mediated diseases such as cancer.... Agent: Bayer Healthcare LLC

20140336209 - Nitrogen-containing six-membered aromatic ring derivatives and pharmaceutical products containing the same: in which Nx group is preferably a 6-membered aromatic ring containing two nitrogen atoms; R0, R1 and R2 are each independently a hydrogen atom, an alkyl group, an amino group or the like; E is an oxygen atom or an —NR8 group (wherein R8 is an alkyl group or the... Agent:

20140336211 - Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [ (s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino) -ethyl ] -amide: The present invention relates to polymorphs and hydrates of 2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carboxylic acid [(S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide, processes for their preparation and their use, in particular in pharmaceutical compositions.... Agent:

20140336213 - Abuse deterrent compositions and methods of making same: This invention relates a therapeutic pharmaceutical composition comprising: a mixture including an opioid; polyethylene oxide in an amount of about 3 to about 40 wt % of the composition; a disintegrant; and a surfactant; wherein the disintegrant is present in an amount sufficient to cause the pharmaceutical composition to exhibit... Agent: Acura Pharmaceuticals, Inc.

20140336212 - Combination analgesic employing opioid agonist and neutral antagonist: In some embodiments, the invention provides a non-addictive analgesic co-formulation comprising an opioid agonist in an amount sufficient to confer analgesia in a mammalian subject (such as a human) and a neutral opioid antagonist in an amount sufficient to inhibit peripheral effects of the opioid agonist, and insufficient to block... Agent: Aiko Biotechnology

20140336214 - Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound: The present invention relates generally to the co-administration of an opioid agonist compound and an analgesic compound. In addition, the invention relates to, among other things, dosage forms for co-administration of an opioid agonist compound and an analgesic compound, methods for administering an opioid agonist compound and an analgesic compound,... Agent:

20140336215 - Rhinitis treatment regimens: A method of treating rhinitis and rhinorrhea includes taking a daytime oral dosage unit containing a non-sedating antihistamine for treating rhinitis and an anticholinergic agent having limited capacity to cross blood-brain barrier for treating rhinorrhea, and taking a nighttime oral dosage unit containing a non-sedating anticholinergic agent that has limited... Agent:

20140336216 - Physiological ligands for gpr139: Provided herein are compounds capable of activating GPR139. Also provided are methods of increasing and decreasing the activity of GPR139. Methods of using the identified compounds to modulate GPR139 activity or conditions that may be affected by GPR139 activity are also disclosed.... Agent: Janssen Pharmaceutica Nv

20140336217 - Crystalline forms of prasugrel salts: Salts of prasugrel were prepared including, for example, crystalline forms of prasugrel hydro bromide. These salts are useful, for example, in medicaments that inhibit the aggregation of platelets.... Agent:

20140336218 - Arformoterol and tiotropium compositions and methods for use: Compositions and methods for the prevention and/or treatment of airway and/or respiratory disorders are provided. The compositions comprise arformoterol (the (R,R)-formoterol isomer) and tiotropium.... Agent: Sunovion Pharmaceuticals Inc.

20140336220 - Composition for preventing or treating obesity comprising rebamipide: The present disclosure relates to a composition and a health functional food for preventing or treating obesity comprising a rebamipide compound or its pharmaceutically acceptable salt as an active component. It is confirmed that when a rebamipide compound of the present disclosure is administered to a mouse model induced with... Agent:

20140336219 - Pharmaceutical compositions and administrations thereof: The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, solids forms, and pharmaceutical compositions thereof for the treatment of CFTR mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.... Agent:

20140336221 - Antibiotic and anti-parasitic agents that modulate class ii fructose 1, 6-bisphosphate aldolase: This invention provides a family of compounds that inhibit Class II fructose 1,6-bisphosphate aldolase (FBA), which is implicated in the pathogenic activity of a broad range of bacterial and parasitic agents. The compounds were identified by empirical testing, and provide a basis for further derivatization and optimization of 8-hydroxyquinoline-2-carboxylic acid... Agent: Regis University

20140336222 - Substituted piperidines that increase p53 activity and the uses thereof: i

20140336223 - Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione: Pharmaceutical compositions and single unit dosage forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer or an inflammatory disease.... Agent:

20140336224 - Mineralocorticoid receptor antagonists: Compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, that may be useful for treating aldosterone-mediated diseases are disclosed. Processes for preparing compounds of the Formula (I), use of the compounds for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose,... Agent:

20140336225 - Kinase modulators for the treatment of cancer: Compounds of the substituted pyrazole class as treatments for cancer are reported. A method of treating cancer in which a compound that inhibits the activity of receptor kinases. Said method is effective and can be provided in addition to standard therapies, notably chemotherapy using cytotoxic drugs and other forms of... Agent:

20140336226 - Salt of (r)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl) ethyl propionate: The invention relates to the salt of naphthalene-1,5-disulfonic acid with (R)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1H-imidazol-4-yl)ethyl propionate, which can be represented by the following structural formula of formula (I), to methods for the production thereof, to drugs containing said salt, and to the use of said drugs to treat diseases that are accompanied by... Agent:

20140336227 - 3-amino lactams as anti-inflammatory agents: the compound comprises an amino lactam ring linked to an alkyl group —Yk—(R1)n by an amide group, wherein the carbon atom in the alkyl group at the 2-position relative to the carbon atom of the amide carbonyl is linked to each of the carbon atom of the amide carbonyl and... Agent: Cambridge Enterprise Limited

20140336228 - Pharmaceutical composition for preventing or treating hypertriglyceridemia or hypertriglyceridemia-associated diseases: Provided is a pharmaceutical composition for preventing or treating hyperlipidemia comprising (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one or its pharmaceutically acceptable salt; and a calcium channel blocker or a fibrate as active ingredients.... Agent: Daewoong Pharmaceutical Co., Ltd.

20140336229 - Pharmaceutical composition for preventing or treating hyperlipidemia: Provided is a pharmaceutical composition for preventing or treating hyperlipidemia comprising (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one or its pharmaceutically acceptable salt; and an angiotensin II receptor blocker as active ingredients.... Agent: Daewoong Pharmaceutical Co., Ltd.

20140336230 - Method of increasing metabolism: The present invention provides a method for increasing metabolism and/or energy expenditure in a subject, e.g., to treat or prevent obesity and/or a related condition and/or the reduce adiposity, the method comprising increasing the level and/or activity of Hypoxia Induced Factor 1α (HIF-1α) in a cell, tissue or organ of... Agent: Garvan Institute Of Medical Research

20140336231 - Active compounds combinations comprising prothioconazole and fluxapyroxad: The present invention relates to active compound combinations, in particular within a fungicide composition, which comprises (A) prothioconazole and (B) fluxapyroxad and optionally (C) a further fungicidally active compound. Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungicidally of plants or crops (e.g. cereals... Agent:

20140336232 - 2-iodo imidazole-derivatives: The present invention relates to novel 2-iodoimidazole derivatives, to processes for preparing these compounds, to compositions comprising these compounds and to their use as biologically active compounds, in particular for controlling harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators.... Agent:

20140336233 - Use of tetramic acid derivatives for controlling pathogens by foliar application: Compounds of the formulae (I) and (II) for controlling pathogens by foliar application.... Agent: Bayer Intellectual Property Gmbh

20140336234 - Chlorophyll c containing degranulation suppressor: Degranulation suppressors are provided that are effective against allergic disease and osteoarthritis. The degranulation suppressors contain chlorophyll c.... Agent:

20140336235 - Substituted biaryl alkyl amides: Disclosed herein are substituted biaryl alkyl amide compounds, methods of synthesizing substituted biaryl alkyl amide compounds and methods of treating diseases and/or conditions with substituted biaryl alkyl amide compounds.... Agent:

20140336246 - Process for preparing amorphous cabazitaxel: s

20140336247 - Daidzein derivative, pharmaceutically acceptable salt and preparation method thereof, and pharmaceutical composition containing same: Disclosed is a daidzein derivative as represented by formula (I), or pharmaceutically acceptable salt thereof. Compared to the daidzein in the prior art, the daidzein derivative hydrochloride, in particular to the 7-O—N,N-diethyl-aminoacetyl daidzein hydrochloride, prepared by the daidzein derivative of the present invention, has better solubility and effect for treating... Agent:

20140336248 - Therapeutic compositions and related methods of use: Aqueous compositions comprising salinomycin, or a pharmaceutically acceptable salt thereof, miscible organic solvents, and solubilizers and/or emulsifying agents are disclosed. The formulations disclosed herein are useful in the treatment of cancer, especially cancers associated with cancer stem cells or cancerous mesenchymal cells. The method of treating a subject may further... Agent:

20140336249 - 2-alkyl-or-aryl-substituted tanshinone derivatives, and preparation method and application thereof: The present invention belongs to the field of natural medicine and pharmaceutical chemistry, and specifically relates to novel 2-alkyl- or 2-aromatic-substituted tanshinone I derivatives of formula (I) or a pharmaceutically acceptable salt thereof, to a process for the preparation of these compounds, compositions containing such compounds and their use in... Agent:

20140336250 - Method for treating bronchial diseases: Administration of a loop diuretic in nebulized dry powder form directly to a patient's lungs for treating bronchial disease.... Agent:

20140336251 - Methods of treating age related disorders: The invention generally relates to methods of treating a patient having, and/or at risk of, oxidative distress disorders and/or age-related disorders. The disclosure also generally relates to methods of treating memory impairment or enhancing the cognitive function of a patient in need thereof. Such methods may include administering a therapeutically... Agent: Zafgen, Inc.

20140336252 - Novel compound as kcnq potassium channel agonist, preparation method therefor and use thereof: The present invention provides compounds having the structure represented by general formula I, pharmaceutically acceptable salts thereofagonist, preparation methods therefor and a use thereof in the preparation of a medicine for the treatment of nervous system diseases. The compounds or pharmaceutical compositions thereof can be used as the KCNQ potassium... Agent:

20140336253 - Composition for transdermal administration of rivastigmine: It has been found that phenyl carbamates, in particular Rivastigmine, can be formulated as a stable TTS by using a monolayer poly alkyl (meth)acrylates, wherein the poly alkyl (meth)acrylates are substantially free of free carboxylate groups.... Agent:

20140336254 - Small molecules that covalently modify transthyretin: reacts chemoselectively with one or two of four Lys-15 ε-amino groups within the transthyretin tetramer. The crystal structure confirms the binding orientation of the compound substructure and the conjugating amide bond. A covalent transthyretin kinetic stabilizer exhibits superior amyloid inhibition potency, compared to a non-covalent counterpart, and inhibits cytotoxicity associated... Agent:

20140336255 - Insecticidal formulations with improved long-term effect on surfaces: The present invention relates to compositions for the control of pests, in particular insecticidal suspension concentrates and spray solutions made from them, to processes for their preparation, and to the use of such formulations for the sustained control of animal pests (arthropods) on a variety of surfaces. The present invention... Agent:

20140336256 - Method of treating tourette's disorder with gaba-aminotransferase inactivators: The present invention is a method of treating Tourette's Disorder (TD) using GABA ergic drugs that elevate the amount of stored presynaptic GABA and do not significantly increase GABA tone (a continuous background level of GABA signaling) in the brain. The administration of vigabatrin and/or (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride salt is... Agent: The Feinstein Institute For Medical Research

20140336257 - Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris: A regimen for the safe and effective long-term treatment of acne vulgaris entails topically applying onto the affected skin area of a subject afflicted therewith, for a period of time of at least four (4) months, e.g., for at least twelve (12) months and advantageously on a daily basis and... Agent:

20140336258 - Anti-virulence compositions and methods: A method of reducing the virulence of a bacterium that expresses accessory gene regulator A (AgrA) includes administering to the bacterium an amount of AgrA antagonist effective to inhibit the synthesis of one or more virulence factors by the bacterium.... Agent:

20140336259 - Phenolic compounds with antioxidant and anti-cancer properties, analogs and synthesis thereof: The present document describes a phytochemical isolated from maple syrup and composition comprising the same. More specifically, the document describes an antioxidant phytochemical compound, derivates thereof, and composition comprising the same. The document also describes a process of synthesizing the antioxidant phytochemical compound.... Agent:

20140336260 - Product for mold prevention and treatment: A novel product for mold prevention and treatment is disclosed herein. The product comprises water, one or more anti-mold agents, one or more water-soluble fluoropolymers or other water-soluble polymers with similar properties, and one or more emulsifiers. In some embodiments, the product may further comprise one or more preservatives, one... Agent:

20140336261 - Methods for determining aggressiveness of a cancer and treatment thereof: The invention generally relates to methods for determining aggressiveness of a cancer and treatment thereof. Certain aspects of the invention provide methods that involve conducting an assay on a lipid droplet in order to detect an amount of a biomarker within the lipid droplet, and determining aggressiveness of a cancer... Agent:

20140336262 - Pharmaceutical compositions comprising napthamides: Disclosed herein are naphthamide and quinoline carboxamide compounds containing two bicyclic moieties, pharmaceutical compositions comprising those compounds and methods of using the compositions in the treatment of cancers mediated by cyclic-AMP (cAMP) response element binding protein (CREB). The disclosed compositions have utility in the treatment of lung, prostate and breast... Agent: Oregon Health & Science University

20140336263 - Animal deterrent system and methods thereof: An animal deterrent device that generally includes a casing, a sensor, a power source and a deterrent means source. The animal deterrent device is used to provide protection to a target site, such as a carcass or part of a carcass left at or near the kill site from predatory... Agent: Grizzly Mountain Enterprises LLC

20140336265 - Dosage regimen of diaryl sulfide derivatives: wherein said compound of formula I or II is administered at a dosage lower than the standard daily dosage of said compound during the initial period of treatment and then is increased, optionally stepwise, up to the standard daily dosage of said compound.... Agent: Novartis Ag

20140336264 - Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.... Agent: Tonix Pharmaceuticals, Inc.

20140336266 - Method for administering an nmda receptor antagonist to a subject: Compositions and methods for administering memantine to a subject are provided. In particular, a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided. The compositions comprises an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein... Agent: Adamas Pharmaceuticals, Inc.

20140336267 - Utilization of the function of rare sugar as promoter for the migration of glucokinase from nucleus to cytoplasm: A composition for treating disordered conditions in association with glucokinase activity contains a glucokinase-activating substance as the active ingredient. A promoting agent of glucokinase transfer from nucleus to cytoplasm contains D-psicose and/or D-tagatose as the active ingredient or a composition for preventing the onset of disordered conditions in association with... Agent: Matsutani Chemical Industry Co., Ltd.

20140336268 - Formulations of vitamin k analogs for topical use: The present invention provides topical formulations containing a vitamin K analog, e.g., menadione, that deliver a uniform, therapeutically effective concentration of the vitamin K analog to the skin in a vehicle which is stable, non-irritating, non-drying and cosmetically acceptable. These topical formulations are useful for the treatment and prevention of... Agent:

20140336269 - Methods and compositions for controlling pests: The present invention is directed to pest-controlling compositions comprising as active ingredients one or more β-diones, particularly β-diketones and β-triketones, and to the use of these compositions inter alia for preventing, eradicating, destroying, repelling or mitigating harmful, annoying or undesired pests including insects, arachnids, helminths, molluscs, protozoa and viruses. The... Agent:

20140336270 - Method for synthesizing (e)-anethol and related compounds by cross coupling reaction of potassium allyltrifluroborate and 4-bromoanisole and aryl halides: Methods of producing substituted and non-substituted beta-methyl styrene by a cross-coupling reaction are provided. The disclosure also provides for methods of preparing (E)-Anethol and related compounds by a cross coupling reaction of potassium allyltrifluoroborate and 4-bromoanisole and aryl halides. Compounds, compositions, and methods of treating disorders utilizing beta-methyl styrene are... Agent: Tennessee Board Of Regents

20140336271 - Antimicrobial compositions containing carvacrol and thymol: Compositions having a combination of carvacrol and thymol are found to have synergistic antimicrobial activity against feed pathogens.... Agent:

20140336272 - Petrolatum composition: A petrolatum composition comprises from 10 to 60 wt % of a wax having an average number of carbon atoms per molecule of between 25 and 70, and having between 5 and 50 wt % branched paraffins in which the branches are selected from methyl and ethyl branches; from 10... Agent:

20140336273 - Anhydrous sodium carbonate having a low pore content: The present invention relates to a highly pure, anhydrous sodium carbonate having a low pore content for use in pharmaceutical formulations and in the foods industry. Furthermore, a novel process for the preparation of this sodium carbonate is provided.... Agent: Merck Patent Gmbh

20140336274 - Process for producing inorganic particulate material: The present invention is directed to a process for producing inorganic particulate material, the material obtainable by such process, a modified release delivery system comprising the material and the use of the material for the administration of a bioactive agent.... Agent: Merck Patent Gmbh

20140336275 - Modular emulsion-based product differentiation: A micro-scale heterogeneous emulsion is provided. In some examples, the micro-scale heterogeneous emulsion can include at least two internal phases and an external phase. A method of producing a micro-scale heterogeneous emulsion is also disclosed herein. A method of providing a stable, custom cosmetic composition is also disclosed herein.... Agent: The Procter & Gamble Company

20140336276 - In situ crosslinking hydrogel comprising gamma-polyglutamic acid and method for producing the same: Disclosed are a biodegradable, biocompatible hydrogel that can be used for sealants of suppressing the leakage of blood or air during surgical operation, tissue adhesives, anti-adhesive agents and drug delivery carriers, and a method for producing the same... Agent:

20140336277 - Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof: Radiopaque, iodinated, absorbable polyesters, polyester urethanes, and polyether-ester-urethanes with and without inorganic iodide micro-/nanoparticles dispersed or solubilized therein, and composite inorganic iodide micro-/nanoparticles in an absorbable polyester, polyester-urethane, polyester-ester, or polyether-ester urethane matrix are employed in medical devices and therapeutic compositions.... Agent: Poly-med, Inc.

20140336278 - In situ gelling drug delivery system: The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance... Agent:

20140336279 - Use of a vaporizable composition to protect cultivated plants from pests: The disclosure relates to the use of an oil emulsion for acaricidal, insecticidal, and antifungal treatment of the stems and leaves of a plant during the growth thereof in confined, intensive-cultivation spaces, the emulsion including water and a paraffin oil obtained from petroleum and having a boiling point of 200°... Agent: Total Marketing Services

20140336280 - Compositions and methods for detecting and determining a prognosis for prostate cancer: The present disclosure provides methods of detecting and determining the aggressiveness of prostate cancer. These methods can be used to determine whether or not a patient needs a biopsy as well as guide treatment selection.... Agent: Neogenomics Laboratories, Inc.

20140336283 - Genetic factors in blood pressure: The invention describes epistatic interactions between single nucleotide polymorphisms on genes associated with blood pressure and provides an application for their use in a method to determine an individual's susceptibility to hypertension and hence whether anti-hypertensive treatment will be beneficial for said individual. In addition gene expression levels are also... Agent: Randox Laboratories Ltd.

20140336282 - Molecular signatures of invasive cancer subpopulations: Carcinomas typically invade as a cohesive multicellular unit, a process termed collective invasion. It remains unclear how different subpopulations of cancer cells contribute to this process. We developed three-dimensional (3D) organoid assays to identify the most invasive cancer cells in primary breast tumors. Collective invasion was led by specialized cancer... Agent: The Johns Hopkins University

20140336281 - Srm/mrm assay for the ephrin typa-a receptor 2 protein: Specific peptides, and derived ionization characteristics of the peptides, from the Ephrin Type-A Receptor 2 (EPHA2) protein are provided that are particularly advantageous for quantifying the EPHA2 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what... Agent:

  
11/06/2014 > 182 patent applications in 142 patent subcategories.

20140329737 - Development of novel macromolecule transduction domain with improved cell permeability and method for using same: The present invention relates to an improved macromolecule transduction domain (MTD), which facilitates permeating the cell membrane of a biologically active molecule, having enhanced cell permeability. Specifically, an improved MTD according to the present invention, compared to an existing MTD, can transmit various types of biologically active molecule from inside... Agent: Procell Therapeutics Inc.

20140329738 - Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as... Agent:

20140329740 - Anti-infective hydroxy-phenyl-benzoates and methods of use: The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analogue. The extracellular microorganism can be of the bacterial... Agent: Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center

20140329739 - Antibiotic peptide and preparation method therefor and application therefor: Disclosed are an antibiotic peptide and the like, having an amino acid sequence of Ac-Phe-Lys-Lys-Leu-Lys-Lys-Leu-Phe-Ser-Lys-Leu-Trp-Asn-Trp-Lys-NH2 (SEQ ID No:1). Also disclosed are a method of preparing the antibiotic peptide and the like, and the application thereof. The antibiotic peptide and the like synthesized by the solid phase synthetic technology according to... Agent: Jiangsu Protelight Pharmaceutical & Biotechnology Co., Ltd.

20140329741 - Use of cyclic peptides from flaxseed for improving animal and human health: The present application includes a method for improving human and animal health comprising administering an effective amount of a linus cyclopeptide (LCP) extract from flaxseed to a subject in need thereof. Also included are feeds, foodstuffs, functional food compositions, natural product compositions nutraceuticals and food additive compositions comprising an LCP... Agent:

20140329742 - Therapeutic peptides: The present invention relates to novel analogs of PYY that have an improved therapeutic profile when compared to native human PYY. These novel PYY analogs are useful in the treatment of obesity, diabetes, and other disorders.... Agent: Glaxosmithkline Intellectual Property (no. 2) Limited

20140329743 - Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers: A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to a-melanocortin stimulating... Agent:

20140329745 - Human insulin analogue and acylated derivative thereof: The present invention provides a human insulin analogue, an acylated derivative thereof and a physiologically acceptable salt. The present invention further provides a preparation method for the insulin analogue and an application of the insulin analogue as a therapeutic agent, and particularly as a diabetes mellitus therapeutic agent.... Agent:

20140329744 - Stable non-aqueous liquid pharmaceutical compositions comprising an insulin: The invention describes a non-aqueous liquid pharmaceutical composition comprising at least one lipid and at least one insulin. Also described is a method of producing a pharmaceutical composition comprising a lipid and a method of purifying a lipid, a cosolvent, a surfactant or a pharmaceutical composition comprising a lipid.... Agent:

20140329746 - Methods and compositions for treating amyloid-related diseases: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.... Agent:

20140329747 - Compositions and methods for treating renal failure: The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of renal failure, especially renal failure associated with cirrhosis.... Agent: La Jolla Pharmaceutical Company

20140329748 - Composition for controlled ovarian stimulation: Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility.... Agent: Ferring Bv

20140329749 - Robust controlled-release peptide formulations: The present invention relates to compositions forming a low viscosity mixture of: a. 25-55 wt. % of at least one diacyl glycerol and/or at least one tocopherol; b. 25-55 wt. % of at least one phospholipid component comprising phospholipids having i. polar head groups comprising more than 50% phosphatidyl ethanolamine,... Agent:

20140329750 - Growth hormones with prolonged in-vivo efficacy: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.... Agent:

20140329751 - Method for sensitizing cells to cancer therapy: Disclosed herein are compositions and methods useful for the treatment of cancer, such as breast cancer. In some embodiments, the methods and compositions include human prolactin, or human prolactin in conjunction with a cytotoxic agent. In other embodiments, the methods and compositions include one or more of human prolactin, growth... Agent: Orbis Health Solutions LLC

20140329752 - Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use: The embodiments provide a modified calcitonin gene-related peptide antagonist including an N-terminal fragment of modified calcitonin gene-related peptide or related protein family member where at least two residues of the N-terminal fragment are cysteine (Cys) and at least one amino acid comprises a non-threonine substitution of a threonine (Thr) residue;... Agent:

20140329753 - Angiogenic active lytic peptides: This invention relates to novel synthetic lytic peptide fragments of full-length peptides with the capacity to modulate angiogenic activity in mammals. The invention also relates to the use of such peptides in pharmaceutical compositions and in methods for treating diseases or disorders that are associated with angiogenic activity.... Agent:

20140329754 - Compositions and methods for treating myelodysplastic syndrome: This invention generally relates to compositions and methods for treating myelodysplastic syndrome. In one embodiment, this invention relates to methods for treating myelodysplastic syndrome with ezatiostat or a salt thereof and lenalidomide.... Agent: Telik, Inc.

20140329755 - Combination therapy for the treatment of arrhythmias or heart failure: The present invention relates to method of treating arrhythmias or heart failure comprising co-administration of a late INa inhibitor and a CAMK II inhibitor.... Agent: Gilead Sciences, Inc.

20140329756 - Temperature-release catalyst for cross-linking halyuronic acid during injection: Systems and methods for cosmetic augmentation by forming a biocompatible cross-linked polymer having a multi-phase mixture with a temperature activated catalyst; injecting the mixture into a patient as a homogeneous fluid; activating the catalyst to cross-link the polymer at a predetermined temperature in a patient; and augmenting soft tissue with... Agent: Miba Medical Inc.

20140329757 - Tubulin-interacting protein, caltubin, promotes axonal growth: A novel isolated protein, referred to herein as “caltubin”, is provided. Caltubin promotes axonal regeneration, and prevents or at least reduces axonal retraction in neurons.... Agent: University Of Toronto

20140329758 - Peptide inhibitors for mediating stress responses: The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides.... Agent:

20140329759 - Polyethylene glycol-modified integrin blocker hm-3 and use thereof: The present invention involves the pharmaceutical field, including integrin antagonists, which have the capacities of inhibiting angiogenesis of tumors, binding integrin. These antagonists are a kind of polypeptide, which was modified by polyethylene glycol and after modification, it can be used to treat tumors. The sequence and structure of these... Agent:

20140329760 - Peptides and nanoparticles for therapeutic and diagnostic applications: Provided herein are peptides and nanoparticles conjugates thereof useful for the treatment of diseases and disorders mediated by GIPC/synectin, such as cancer.... Agent: Trustees Of Dartmouth College

20140329761 - Prevention and treatment of acute inflammatory conditions: The present invention relates generally to methods for the prevention and treatment of acute inflammatory conditions in individuals using an agonist of the complement C3a receptor.... Agent: The University Of Queensland

20140329763 - Anti-influenza nucleic acid, peptide nucleic acid and preparations thereof: Disclosed are an anti-influenza nucleic acid, peptide nucleic acid and preparations thereof. The nucleic acid of the invention consists of any one or several of SEQ ID NOs: 1-12, and any one or several of SEQ ID NOs: 13-24. The peptide nucleic acid of the invention consists of any one... Agent:

20140329762 - Compositions for treating muscular dystrophy: Improved compositions and methods for treating muscular dystrophy by administering antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping are described.... Agent: Sarepta Therapeutics, Inc.

20140329764 - Novel methods of use of hsp70 for increased performance or treatment of hsp70 related disorders: The present invention relates to novel therapies that utilize exogenous HSP70 for the treatment of disorders or conditions regulated by HSP70 through administration of exogenous HSP70.... Agent: Alternative Innovative Technologies LLC

20140329765 - Methods and compositions for the treatment of gastrointestinal disorders: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and... Agent: Ironwood Pharmaceuticals, Inc.

20140329766 - Prophylactic compositions for management of microbial infections in patients with brain injury: The present disclosure pertains to antimicrobial compositions for intravenous administration to patients who have experienced a serious brain trauma, to reduce the risk of occurrence of post-trauma microbial infections. The antimicrobial compositions comprise an α-galacytosylceramide compound and one or more excipients. The present disclosure also pertains to the use of... Agent:

20140329767 - Compositions and methods for preventing and treating diseases and environmentally induced health disorders: Nutraceutical or pharmaceutical compositions, functional foods, extracts, dietary supplements and food/feed additives enriched in phytochemicals having antioxidant and/or anti-inflammatory activity may be derived from the skin, pith, or cortex from stem tubers of select potato cultivars, such as Onaway, Russet Burbank, Purple Valley or Bora Valley cultivars. These cultivars and... Agent: The Royal Institution For The Advancement Of Learning/mcgill University

20140329884 - 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof: The present invention provides novel 1,3,5-triazinane-2,4,6-trione derivatives, such as compounds of any one of Formulae (I) and (II), and salts thereof, and methods of preparing the compounds. Also provided are compositions including a compound of the invention and an agent (e.g., an siRNA, mRNA, or plasmid DNA). The present invention... Agent:

20140329879 - Diagnosis and treatment of taxane-resistant cancers: Provided herein are methods and assays relating to the diagnosis and treatment of a taxane-resistant cancer. Such methods and assays comprise determining the level of expression of miR-135a in a biological sample from a subject having or suspected of having a taxane-resistant cancer or from a subject that was or... Agent: Children's Medical Center Corporation

20140329881 - Exon skipping compositions for treating muscular dystrophy: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.... Agent: Sarepta Therapeutics, Inc.

20140329880 - Exonuclease resistant polynucleotide and related duplex polynucleotides, constructs, compositions, methods and systems: Provided herein are exonuclease resistant polynucleotides and related constructs, compositions, methods and systems.... Agent: California Institute Of Technology

20140329885 - Lipids, lipid complexes and use thereof: o

20140329887 - Microrna compounds and methods for modulating mir-21 activity: Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.... Agent:

20140329882 - Oligomeric compounds and compositions for use in modulation of small non-coding rnas: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment... Agent: Regulus Therapeutics Inc.

20140329878 - Oligonucleotide modulators of the toll-like receptor pathway: Disclosed herein are double stranded nucleic acid molecules and pharmaceutical compositions comprising same useful in the treatment of, inter alia, acute and chronic inflammation, neuropathic pain, primary graft dysfunction (PGD) after lung transplantation in a subject in need thereof. The compounds are preferably chemically synthesized and modified dsRNA compounds, which... Agent:

20140329883 - Pharmaceutical composition comprising anti-mirna antisense oligonucleotides: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 26 nucleobases which are complementary to human microRNAs selected from the group consisting of miR19b, miR21, miR122a, miR155 and miR375. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is... Agent: Santaris Pharma A/s

20140329886 - Single-stranded nucleic acid molecule having amino acid backbone: The invention provides a single-stranded nucleic acid molecule containing an expression inhibitory sequence that inhibits expression of a target gene, region (X), linker region (Lx), and region (Xc), wherein the linker region (Lx) is linked between the region (Xc) and the region (Xc), the region (Xc) is complementary to the... Agent:

20140329888 - Compositions and methods for the intracellular disruption of vegf and vegfr-2 by intraceptors: The present invention provides an intraceptor that interacts with and decreases activity of with VEGF and/or a VEGFR for the treatment of angiogenesis-related conditions. The present invention further provides pharmaceutical compositions, and methods of use thereof, for the treatment and prevention of an angiogenesis-related condition using said intraceptors. The invention... Agent:

20140329890 - Compounds having anti-adhesive effects on cancer cells: Compounds of the form O-(x-L)n, where O is an oligonucleoside having at least a plurality of N3′→P5′ thiophosphoramidate (NPS) internucleoside linkages, a conjugated lipid moiety L, and at least one G-rich sequence motif as described, are effective to morphologically alter and reduce adhesion of cancer cells.... Agent: Board Of Regents Of The University Of Texas System

20140329889 - Cyclic di-nucleotide induction of type i interferon: Methods and compositions are provided for increasing the production of a type I interferon (IFN) in a cell. Aspects of the methods include increasing the level of a 2′-5′ phosphodiester linkage comprising cyclic-di-nucleotide in a cell in a manner sufficient to increase production of the type I interferon (IFN) by... Agent:

20140329891 - In vitro and in vivo delivery of genes and proteins using the bacteriophage t4 dna packaging machine: Described is T4 DNA packaging machine comprising: one or more DNA molecules packaged in a head of the T4 DNA packaging machine, one or more Hoc-fused proteins displayed on the head of the T4 DNA packaging machine, and one or more Soc-fused proteins displayed on the head of the T4... Agent:

20140329768 - Vitamin b6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates: Provided herein are compounds, compositions, and methods of using them to treat infections, neoplastic disease, inflammatory disease, and pain. Such compounds are nucleotides, acyclonucleotides, and ANP phosphonates conjugated with forms and/or moieties of Vitamin B6 for delivery past the cell membrane and into the cell.... Agent: Mbc Pharma, Inc.

20140329770 - Compositions comprising phytoestrogens receptor beta agonists and dietary fibers for chemopreventive treatment of sporadic adenomatous polyposis: It is herein discloses compositions comprising a blend of dietary phytoestrogens receptor β agonists and dietary fibers for prevention and treatment of sporadic adenomatous polyposis. The aforementioned compositions proved to be effect in a clinical trial enrolling patients prone to polyp recurrence and at intermediate risk for colorectal cancer (CRC)... Agent:

20140329769 - Oxidized regenerated cellulose hemostatic powders and methods of making: The present invention is directed to hemostatic material containing compacted ORC powder comprising particles having an average aspect ratio from about 1 to about 18, wherein said compacted ORC powder have preferably been processed in a compaction device, such as a ball milled ORC powder. The present invention further relates... Agent: Ethicon, Inc.

20140329771 - Structural variants of mycolactones for use in modulating inflammation, immunity and pain: The present invention is related to variants of mycolactones of formula (I), processes for the preparation thereof, pharmaceutical compositions thereof and their use in modulating inflammation, immunity and pain. Y—O—W (I), wherein Y and W are as defined in claim 1.... Agent:

20140329772 - Induced exon inclusion in spinal muscle atrophy: The invention relates to the use of an antisense compound for inducing exon inclusion as a treatment for Spinal Muscle Atrophy (SMA). More particularly it relates to inducing inclusion of exon 7 to restore levels of Survival Motor Neuron (SMN) protein encoded by the Survival Motor Neuron (SMN) gene.... Agent: Sarepta Therapeutics, Inc.

20140329773 - Compositions for oral administration of zoledronic acid or related compounds for treating disease: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailabilty of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form... Agent:

20140329774 - Injectable composition containing phosphatidylcholine devoid of sodium deoxycholate and preparing method thereof: The present invention includes an injectable composition containing phosphatidylcholine including phosphatidylcholine; ethanol; propylene glycol and/or benzyl alcohol; polysorbate and/or macrogol 15 hydroxystearate; and a balance of water or water for injection, and a preparing method thereof. An injectable composition of the present invention includes no sodium deoxycholate, which is carcinogenic,... Agent:

20140329775 - Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference: Disclosed herein are compositions and methods for generating ribo-nucleic neutral (RNN) or deoxyribo-nucleic-neutral (DNN) polynucleotides with reduced anionic charge, for improved intracellular delivery. Also disclosed herein are methods of using RNN and DNN compositions.... Agent:

20140329776 - Mitochondria-targeted antioxidants for treatment of age-related brain disorders: A method for providing to a mammal a neuroprotective effect against a brain pathology that is associated with reactive oxygen species originating from mitochondria (mROS). The method includes the step of administering to the mammal an SkQ mitochondria-targeted antioxidant in an amount effective to provide said neuroprotective effect. The SkQ... Agent: Mitotech S.a.

20140329777 - Methods to treat infections: Methods to treat infectious diseases are disclosed herein. Some embodiments of the invention include administration of one or more COX inhibitors (e.g., COX-1 or COX-2 inhibitors) to treat infectious diseases. Other embodiments of the invention include administration of one or more COX inhibitors (e.g., COX-1 or COX-2 inhibitors) and administration... Agent:

20140329778 - Compounds for use as anti-ulcer agent and/or anti-helicobacter pylori agent and pharmaceutical compositions thereof: t

20140329779 - Clear solid sticks with solubilized pharmaceutical agents: The invention discloses a solid transparent vehicle utilizing DBS in which a topical pharmaceutical active or cosmetic active is solubilized without the use of a monohydric and/or polyhydric alcohol thus providing a non-tacky, clear solid, which prevents segregation and insures uniformity in dosing.... Agent: Product And Technology Partners LLC

20140329780 - Inhibitor of colonisation of mucosa: The present invention relates in the first aspect to the use of aurintricarboxylic acids, derivatives, oligo- or polymers or salts, for inhibiting adherence and colonisation of microorganisms, like bacteria, on surfaces, in particular for use in mammals. That is, it has been recognized that aurintricarboxylic acids and derivatives thereof are... Agent:

20140329781 - Methods for treating cardiovascular disorder: The present invention relates to a once-a-day therapeutically synergistic pharmaceutical dosage form for treatment of cardiovascular disorders, wherein the dosage form comprises a fixed dose combination of metoprolol in extended release form and one or more antiplatelet agent along with one or more rate controlling excipients.... Agent: Wockhardt Limited

20140329782 - Combined therapeutic agent: The invention relates to a combined therapeutic agent, preferably for use at the prophylactic and/or therapeutic treatment of (A) in particular inflammatory diseases of the respiratory tract, in particular bronchopulmonary diseases, or of (B) in particular inflammatory diseases of the gastrointestinal tract, in particular of the intestine. The combined therapeutic... Agent:

20140329784 - 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations: The present invention relates to new formulations containing one or more estrogens and 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below:... Agent:

20140329783 - Transdermal hormone replacement therapies: Hormone replacement therapies are provided comprising solubilized progesterone alone and optionally with an estrogen, cyclic/sequential and continuous-combined dosing, and administered via transdermal HRT delivery systems.... Agent:

20140329786 - Combination treatment of cancer: The present invention relates to a combination comprising AZD5363, or a pharmaceutically acceptable salt thereof, and at least one androgen receptor signalling modulator selected from MDV-3100 (also known as enzalutamide), AZD3514, abiraterone (or an ester prodrug thereof: e.g. abiraterone acetate), and bicalutamide; or a pharmaceutically acceptable salt thereof. Each of... Agent: Astrazeneca Ab

20140329785 - Conveniently injectable or implantable sustained-release antioxidant formulations for therapies of ocular maladies or cancer: The present embodiments provide for sustained release formulations of antioxidants that are useful in treating afflictions of the eye and tumors.... Agent: Ramscor, Inc.

20140329787 - Phytophthora phospholipase c: The present invention relates to a novel Phytophthora phospholipase C and uses thereof, methods of identifying modulators and inhibitors of a biological function of the phospholipase C, and methods of inhibiting Phytophthora growth comprising inhibiting a biological function of a novel Phytophthora phospholipase C.... Agent:

20140329789 - Methods for inhibiting the development of huntington's disease: This invention relates to Huntington's disease and more specifically to methods for inhibiting the development of or treating Huntington's disease by administering estrogen, testosterone, precursors thereof or combinations thereof.... Agent:

20140329788 - Testosterone gel and method of use: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.... Agent: Unimed Pharmaceuticals, LLC

20140329790 - Use of 5 alpha-androstane-3 beta,5,6 beta-triol in preparation of neuroprotective drugs: Disclosed is the use of 5α-androstane-3β,5,6β-triol in preparing neuroprotective drugs. The compound has significant protective effect against neuron injuries caused by cerebral ischemia, spinal cord ischemia or hypoxia and has no obvious toxic reaction within effective dose thereof.... Agent: Guangzhou Cellprotek Pharmaceutical Ltd.

20140329791 - Compounds and related methods for treatment of neurodegenerative diseases: Aspects of the invention pertain to chemical compounds, therapeutic compositions, and methods for treating neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau.... Agent: University Of South Florida

20140329792 - Synthetic catalase/superoxide dismutase mimetics and methods for treating viral infections: The invention provides for the treatment of disorders related to viral infection, using salen manganese compounds.... Agent:

20140329793 - Pharmaceutical compositions and uses thereof: The invention features pharmaceutical compositions including (i) a drug, and (ii) a PEG fatty acid ester or PPG fatty acid ester in an amount sufficient to increase the oral bioavailability of the drug.... Agent: Seachaid Pharmaceuticals, Inc.

20140329796 - Heterocyclic amide derivative and pharmaceutical product containing same: e

20140329795 - Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an... Agent:

20140329794 - Prmt5 inhibitors and uses thereof: Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.... Agent: Epizyme, Inc.

20140329798 - Substituted cyclopropyl compounds useful as gpr119 agonists: Substituted cyclopropyl compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included... Agent:

20140329797 - Substituted oxadiazolyl pyridinones and oxadiazolyl pyridazinones as hif inhibitors: The present application relates to novel substituted 5-(1,2,4-oxadiazol-5-yl)pyridin-2-ones and 6-(1,2,4-oxadiazol-5-yl)pyridazin-3-ones, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for producing medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and... Agent: Bayer Intellectual Property Gmbh

20140329799 - Aminopyrimidinones as interleukin receptor-associated kinase inhibitors: This invention relates to aminopyrimidinone compounds of Formula (I) that are inhibitors of Interleukin receptor-associated kinases, in particular IRAK-4, and are useful in the treatment or prevention of inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.... Agent:

20140329801 - Sulphonylaminopyrrolidinone derivatives, their preparation and their therapeutic application: The invention relates to new sulphonylaminopyrrolidinone compounds having antithrombotic activity which, in particular, inhibit blood clotting factor IXa and/or factor Xa, to processes for their preparation and to use thereof as drugs.... Agent:

20140329800 - Tri-heterocyclic derivatives, preparation process and uses thereof: The present invention relates to a tri-heterocyclic derivatives, preparation process and uses thereof, specifically relates to a tri-heterocyclic derivatives of the formula (I) or a pharmaceutically acceptable salt thereof, preparation process, and further relates to a pharmaceutically acceptable composition comprising compounds of formula (I), or a pharmaceutically acceptable salt thereof,... Agent:

20140329802 - Tetrahydrobenzothiophene compound: wherein, R1 represents —O-lower alkyl, -lower alkylene-phenyl, or the like; R2 and R3 are the same as or different from each other and represent H, lower alkyl, cycloalkyl, aryl, heteroaryl or the like, or, R2 and R3 may be combined with a nitrogen atom to which they bind to form... Agent: Astellas Pharma Inc.

20140329803 - Muscarinic m1 receptor agonists: This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is... Agent:

20140329804 - Novel phosphodiesterase inhibitors and uses thereof: The invention provides for novel benzonaphthyridine derivatives and compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the compounds are phosphodiesterase inhibitors. The invention further provides for methods for inhibition of phosphodiesterase comprising contacting phosphodiesterase with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. The invention further provides for methods... Agent:

20140329805 - Dual small molecule inhibitors of cancer and angiogenesis: The present invention provides analogs and derivatives of thalidomide which inhibit cancer and angiogenesis. The present invention further provides compounds which disrupt microtubule polymerization. The present further provides methods of treating cancers comprising mutant p53.... Agent: University Of Virginia Patent Foundation

20140329806 - Novel solid forms: e

20140329807 - Heterocyclic protein kinase inhibitors: The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory... Agent: Tolero Pharmaceuticals, Inc.

20140329809 - New leukocyte infiltrate markers for rosacea and uses thereof: A process for the characterization of rosacea is disclosed. The process can include identifying for the first time new markers in leukocyte recruitment as well as the therapeutic applications targeting rosacea.... Agent: Galderma Research & Development

20140329808 - Tocotrienol derivatives and associated methods: Compositions of matter including (R)-2,5,6,8-tetramethyl-8-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)-1,2,3,8,9,10-hexahydrochromeno[5,6-e][1,3]oxazine and (R)-2,6,8-trimethyl-8-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)-1,2,3,8,9,10-hexahydrochromeno[5,6-e][1,3]oxazine are disclosed herein. Further disclosed are methods of preparation of such compounds and the use of such compounds as anticancer agents.... Agent:

20140329810 - Aerosol fluoroquinolone formulations for improved pharmacokinetics: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.... Agent:

20140329811 - Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases: The present invention provides a method for preferentially reducing the proliferation of cystic epithelial cells in the kidney or bile duct in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to preferentially reduce the proliferation... Agent:

20140329812 - Aryl triazole compounds with antitumoural activity: The present invention relates to aryl triazole derivatives of Formula I having antitumoural activity through, as one possible biological target, the molecular chaperone heat shock protein 90 (Hsp90) inhibition. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where... Agent: Sigma-tau Research Switzerland S.a.

20140329813 - Benzofuran-2-sulfonamides pyridine derivatives as chemokine receptor modulators: The present invention relates to novel benzofuran-2-sulfonamide pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.... Agent:

20140329814 - Compositions for treatment of cystic fibrosis and other chronic diseases: The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions... Agent:

20140329815 - Inhibitors of c-fms kinase: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer,... Agent:

20140329816 - Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an... Agent:

20140329817 - Myxovirus therapeutics, compounds, and uses related thereto: This disclosure relates to antiviral compounds disclosed herein and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions. Typically, the pharmaceutical composition comprises a compound of formula I: Formula I, or salt, prodrug, or ester thereof wherein X, Y, and R1 and R10 to R13 are described... Agent: Emory University

20140329818 - Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof: Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.... Agent:

20140329819 - Insecticidal triazinone derivatives: Compounds of the formula (I) or (I′), wherein the substituents are as defined in claim 1, are useful as pesticides.... Agent: Syngenta Participations Ag

20140329821 - Novel substituted bicyclic aromatic compounds as s-nitrosoglutathione reductase inhibitors: The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.... Agent:

20140329820 - Triazine derivatives: The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R1, R2, R3, and R4 are as defined herein and to the use of the compounds as PDE10 inhibitors.... Agent: Pfizer Inc.

20140329822 - N-piperidin-4-yl derivatives: The invention relates to a N-piperidin-4-yl derivative having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same and to the use of said N-piperidin-4-yl derivatives for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast... Agent:

20140329823 - Dimeric iap inhibitors: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of... Agent: Tetralogic Pharmaceuticals Corporation

20140329825 - Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease: The invention relates to novel trifluoromethyl-oxadiazole derivatives of formula (I), and pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, pharmaceutical combinations thereof, and their use as medicaments, particularly for the treatment of neurodegeneration, muscle atrophy or diabetes/metabolic syndrome via... Agent: Novartis Ag

20140329824 - Therapeutic compositions containing macitentan: The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination of at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof... Agent:

20140329826 - (2r)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine and salts thereof: e

20140329827 - Use of flibanserin for the treatment of pre-menopausal sexual desire disorders: The invention relates to the use of flibanserin for the preparation of a medicament for the treatment of pre-menopausal Sexual Desire Disorders.... Agent: Sprout Pharmaceuticals, Inc.

20140329828 - Oligomer-protein tyrosine kinase inhibitor conjugates: The invention relates to (among other things) oligomer-PTK inhibitor conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over PTK inhibitor compounds lacking a water-soluble, non-peptidic oligomer.... Agent: Nektar Therapeutics

20140329830 - 2-carboxamide-4-piperazinyl-benzofuran derivative: The present invention relates to a compound of formula (I), and to pharmaceutical compositions containing said compound and to the use of said compound in therapy, for instance in treating cognitive disorders, as well as to intermediates useful in the preparation thereof.... Agent: Astrazeneca Ab

20140329829 - Trpv1 antagonists including dihydroxy substituent and uses thereof: and pharmaceutically acceptable derivatives thereof, where R1, R4, R8, R9, and m are as defined herein, compositions comprising an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, pain associated with osteoarthritis, osteoarthritis, UI,... Agent: Shionogi & Co., Ltd.

20140329831 - Novel dopamine d3 receptor ligands and preparation and medical uses of the same: The present invention relates to a novel piperazine derivative represented by Formula I having an activity for regulating dopamine D3 receptor, stereoisomers thereof, pharmaceutically acceptable salts or solvates, and a pharmaceutical composition comprising the compound, a process for preparing the same, and use thereof in the prevention or treatment of... Agent:

20140329832 - Metabolic degradation inhibitors for anti-hyperproliferative agents: The present invention provides methods of increasing an amount of a treatment agent in the body, a cancer or tumor. The methods include administering an inhibitor of the metabolic degradation or conversion of the treatment agent to a subject undergoing treatment for a hyperproliferative disorder with said treatment agent. Methods... Agent:

20140329833 - Lysine demethylase inhibitors for inflammatory diseases or conditions: The invention relates to methods and compositions for the treatment or prevention of inflammation and inflammatory diseases or conditions. In particular, the invention relates to an LSD1 inhibitor, such as a 2-cyclylcylopropan-1-amine derivative, a phenelzine derivative and a propargylamine derivative, for use in treating or preventing inflammation and inflammatory diseases... Agent: Oryzon Genomics, S.a

20140329834 - Small molecule inhibitors of ebola and lassa fever viruses: The present invention relates to compositions and methods for the treatment of infection by enveloped viruses, such as Ebola and Lassa fever viruses.... Agent: President And Fellows Of Harvard College

20140329835 - Dosage form for insertion into the mouth: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding... Agent:

20140329837 - Arylpyrazinones such as but not limited to 3-(4-chlorophenyl-1-ethylpyrazin-2-(1h0)-one: a

20140329836 - Substituted hydroxamic acids and uses thereof: wherein R1, R2, G, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or... Agent: Millennium Pharmaceuticals, Inc.

20140329839 - New crystalline form of pemirolast: There is provided a hemihydrate form of the sodium salt of pemirolast.... Agent: Cardoz Ab

20140329838 - Substituted imidazopyrimidin-5(6h)-ones as allosteric modulators of mglur5 receptors: In one aspect, the invention relates to imidazopyrimidin-5(6H)-one analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with... Agent:

20140329840 - Molecules with potent dhfr binding affinity and antibacterial activity: 7-(substituted) derivatives of 7H-pyrrolo[3,2-f]-quinazoline-1,3-diamines, derivative thereof, and methods of using them are provided. The pharmaceutical formulations prepared from the compounds can be used to treat a variety of conditions, which include, but are not limited to bacterial and fungal infections. The compounds can also be used as a sterilizing or... Agent: Georgia Tech Research Corporation

20140329841 - Neosaxitoxin combination formulations for prolonged local anesthesia: Since each of the site I sodium channel blockers have a unique activity and cannot be used to extrapolate the same effective dosage for another site I sodium channel blocker, studies were conducted to identify dosages of neosaxitoxin (“NeoSTX”) and bupivacaine, alone or in combination with epinephrine, to provide two... Agent:

20140329842 - Protein kinase c inhibitors and uses thereof: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these... Agent: Rigel Pharmaceuticals, Inc.

20140329843 - High dose buprenorphine compositions and use as analgesic: The present disclosure relates to a method of providing prolonged analgesia to a mammal in need thereof. Specifically, the current disclosure is directed to a method of treating pain in a mammal for a prolonged period of time using a single high dose of a buprenorphine formulation.... Agent:

20140329844 - Method of restoring the incretin effect: The present invention relates to methods of treating metabolic syndrome, Type 2 diabetes mellitus, atherogenic dyslipidemia and/or obesity. The present invention also relates to methods of restoring the incretin effect, to restoring physiologic control of glucagon levels, to restoring first-phase insulin secretion, and to restoring the physiologic glucose-dependent insulin secretion.... Agent:

20140329845 - 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists: wherein R1, R2, R3, R4, R5, and R6 are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and... Agent: Theravance, Inc.

20140329847 - Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment: The invention pertains to a method of using oxymorphone in the treatment of pain by providing a patient with an oxymorphone dosage form and informing the patient or prescribing physician that the bioavailability of oxymorphone is increased in patients with renal impairment.... Agent:

20140329846 - Morphinan compounds: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor... Agent:

20140329848 - Deuterated amlexanox: Provided herein is technology relating to deuterated amlexanox and particularly, but not exclusively, to compositions comprising deuterated amlexanox, methods of producing deuterated amlexanox, and uses of deuterated amlexanox.... Agent: The Regents Of The University Of Michigan

20140329849 - Hdac inhibitors to treat charcot-marie-tooth disease: The disclosure relates to diseases in the peripheral nervous system, particularly hereditary neuropathies, such as Charcot-Marie-Tooth (CMT) disease. It is shown that this disease is associated with decreased acetylated tubulin levels, which can be overcome by inhibition of histone deacetylases (HDACs). Using HDAC inhibitors, it is shown herein that the... Agent:

20140329850 - Apoptosis signal-regulating kinase 1 inhibitors: e

20140329851 - Deuterium-enriched prasugrel: The present application describes deuterium-enriched prasugrel, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Deuterx, LLC

20140329852 - N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors: The present invention relates to novel N-(imidazolidin-2-ylidene)quinoline derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.... Agent: Allergan, Inc.

20140329853 - [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors: The present invention relates to novel [1,2,4]triazolopyridine compounds with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.... Agent:

20140329854 - Novel heterocyclic compounds useful in sirtuin binding and modulation: Provided are novel heterocyclic sirtuin binding agents, e.g., N-aryl substituted pyridine dicarboxamides, which are useful as sirtuin modulators. Also provided are methods of using the pyridine dicarboxamide compounds for treating sirtuin mediated disorders and conditions, such as diabetes, cancers, and obesity and diseases related to aging.... Agent: Smb Innovation

20140329855 - Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide: The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.... Agent:

20140329856 - Method of treating pain: The instant application discloses methods of treating, reducing, or preventing pain in a mammal, which may include administering a compound capable of modulating a transient receptor potential channel. In one aspect, the TRP channel may be TRPC4. Types of pain contemplated by the present disclosure include acute, chronic, neuropathic, and... Agent:

20140329857 - Quaternary ammonium compounds useful as muscarinic receptor antagonists: in salt or zwitterionic form or a pharmaceutically acceptable salt thereof, wherein R1-6, a, Z and Q are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to,... Agent: Theravance Biopharma R&d Ip, LLC

20140329858 - Cyclic urea derivatives as androgen receptor antagonists: The present invention is directed to compounds of formula (I) wherein R1, R2, R3, and A are defined herein. The present invention also provides for pharmaceutical compositions comprising a compound of formula (I) as well as to the use of such compounds as androgen receptor antagonists for the treatment of... Agent:

20140329859 - Ionic silicone hydrogels comprising pharmaceutical and/or neuticeutical components and having improved hydrolytic stability: The present invention relates to ionic silicone hydrogel polymers displaying improved thermal stability. More specifically, the present invention relates to a polymer formed from reactive components comprising at least one silicone component and at least one ionic component comprising at least one anionic group. The polymers of the present invention... Agent:

20140329860 - 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases: Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2-substituted-p-quinone derivatives as disclosed herein.... Agent: Edison Pharmaceuticals, Inc.

20140329861 - Neosaxitoxin combination formulations for prolonged local anesthesia: Since each of the site I sodium channel blockers have a unique activity and cannot be used to extrapolate the same effective dosage for another site I sodium channel blocker, studies were conducted to identify dosages of neosaxitoxin (“NeoSTX”) and bupivacaine, alone or in combination with epinephrine, to provide two... Agent:

20140329862 - Glucagon receptor modulators: or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions... Agent: Pfizer Inc.

20140329863 - Novel antiprion compounds: Described herein are novel compositions and methods of treatment addressing diseases such as neurodegenerative diseases, including prion diseases and Alzheimer's disease.... Agent: The Regents Of The University Of California

20140329864 - Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid: The invention relates to a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid which is in a crystalline form or in at least partially crystalline form as a monohydrate or anhydrate, as well as a process for the preparation of the same, methods of using such salt to treat subjects suffering from conditions... Agent:

20140329865 - Pesticidal mixtures: The present invention relates to pesticidal mixtures comprising a component A and a component B, wherein component A is a compound of formula (I) wherein B1, B2, B3, X1, X2, X3, X4, Y1, Y2, Y3, R5, R7, and R8 are as defined in claim 1 and component B is an... Agent: Syngenta Participations Ag

20140329866 - Omega-carboxyarl substituted diphenyl ureas as raf kinase inhibitors: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.... Agent: Bayer Healthcare LLC

20140329867 - Inhibitors of notch signalling pathway and use thereof in treatment of cancers: The present invention relates to use of inhibitors of Notch signalling pathway selected from the group consisting of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), its derivatives, in treating and/or preventing cancers.... Agent: Ecole Polytechnique Federale De Lausanne

20140329868 - Methods for treating hypertension: The present invention relates to methods of treating subjects suffering from pre-hypertension or hypertension by administering to a subject in need of treatment thereof a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof.... Agent:

20140329869 - Compositions and methods for treating amyotrophic lateral sclerosis in responders: A method for treating amyotrophic lateral sclerosis (ALS) in a subject in need thereof comprising administering to said subject an effective amount of (6R)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole or pharmaceutically acceptable salt thereof, wherein said subject is a treatment responder. In certain embodiments, said subject is a subject with definite amyotrophic lateral sclerosis, a... Agent: Knopp Biosciences, LLC

20140329870 - Compositions comprising isosorbide monoesters and isothiazolinones: m

20140329871 - Small molecule anti-fibrotic compounds and uses thereof:

20140329872 - Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy: The invention relates to methods and pharmaceutical compositions for treating hypertension and/or preventing or treating heart failure in a mammal receiving anti-coagulant therapy using compound(s) which are therapeutically effective but do not impact the pharmacokinetic or the pharmacodynamic effect(s) of the anti-coagulant, such as warfarin.... Agent: Novartis Ag

20140329873 - Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid: The meglumine salt of 1-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid (compound (1)) and pharmaceutically acceptable formulations thereof are described. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity.... Agent:

20140329874 - Alpha adrenergic agonists for the treatment of tissue trauma: The present invention provides a method of treating tissue trauma (such as damage from radiation (such as solar and ultraviolet radiation), wounds, bruising, burns, blisters, excoriations, incisions, excisions, and ulcers) in a subject, comprising topically administering to the tissue area of the subject affected by said trauma a composition comprising... Agent: Allergan, Inc.

20140329875 - Alpha adrenergic agonists for the treatment of tissue trauma: The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.... Agent: Jenrin Discovery

20140329876 - Pyrazoline derivatives and their use as selective androgen receptor modulators: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I), in which the substituents are as defined in the specification; to compounds of formula (I) for use as androgen receptor modulators. The present invention further provides a combination of pharmacologically active... Agent: Novartis Ag

20140329877 - Tricyclic compounds, compositions comprising them and uses thereof: Tricyclic compounds, compositions and uses thereof in the treatment of at least one disease, disorder or condition such as for example obesity, overweight, abnormal fat-distribution and any conditions or disease associated therewith.... Agent:

20140329892 - Administration of a bis(thiohydrazide amide) compound for treating cancers: Administration of a bis(thiohydrazide amide) compound is found to be surprisingly effective at treating subjects with cancer. Methods of treating a subject with cancer comprising continuously administering a bis(thiohydrazide amide) compound, or administering a bis(thiohydrazide amide) compound such that a constant concentration of the compound is achieved in the subject,... Agent: Synta Pharmaceuticals Corp.

20140329894 - Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease: The invention relates to compounds, methods, uses, compositions, combinations, kits and packages for the prevention and/or treatment of parasite infection (e.g., Plasmodium parasites) and/or disease (e.g., malaria) based on uses of (a) cystamine, cysteamine, and analogs, derivatives, prodrugs, precursors thereof; an agent capable of inducing their production; and/or salts thereof,... Agent: The Royal Institution For The Advancement Of Learning/mcgill University

20140329893 - Therapeutic compositions: These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the... Agent: Btg International Limited

20140329895 - Oligomer-cannabinoid conjugates: The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated cannabinoid compounds.... Agent:

20140329896 - Compositions and methods of treatment with proanthocyanidin polymer antidiarrheal compositions: Pharmaceutical compositions containing a proanthocyanidin polymer composition which are useful for the treatment and prevention of secretory diarrhea are provided. The invention specifically relates to pharmaceutical formulations of a proanthocyanidin polymer composition which has been isolated from a Croton spp. or a Calophyllum spp. In particular, the invention relates to... Agent:

20140329897 - Composition for treating influenza a (h1n1) virus and a preparation method therefor: New pharmaceutical compositions extracted from Ferula assa-foetida are confirmed to effectively treat influenza A (H1N1) virus. The extraction method of the new pharmaceutical compositions mainly includes steps of: (a) extracting F. assa-foetida with methanol to obtain a crude extract; (b) fractioning the crude extract with n-hexane-methanol to obtain a methanol... Agent:

20140329898 - Cosmetic use of n-substituted sulfonyloxybenzylamines and related compounds: Cosmetic compositions comprising N-substituted sulfonyloxybenzylamines and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. The N-substituted sulfonyloxybenzylamines are believed to have modulatory activity against one or more biochemical pathways implicated in skin aging.... Agent:

20140329899 - Method for producing silver-ion antibacterial liquid, silver-ion antibaterial liquid produced by said method, method for producing silver-ion antibaterial powder, and silver-ion antibaterial powder produced by said method: A method for producing silver-ion antibacterial liquid using a type A or type X silver zeolite includes a process to weigh silver zeolite for obtain its blending quantity in a range of 0.1 to 20.0 percent by weight and to weigh citric acid for obtaining its blending quantity such that... Agent: Taiki Corp., Ltd.

20140329900 - Small molecule inhibitors of stat3 with anti-tumor activity: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The... Agent: University Of South Florida

20140329901 - Compounds for treatment of cell proliferative diseases: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.... Agent: Board Of Regents, The University Of Texas System

20140329902 - Lysine delivery systems for blood coagulation: A blood coagulating device can include an absorbent body; and a hemostatic lysine composition associated with the body. The body can have a cylindrical or conical member having a first end having the hemostatic composition, the first end being configured for insertion into a nasal passageway. A method for coagulating... Agent: Park City Bio, LLC

20140329903 - Treatment of neurodegenerative diseases: The present disclosure relates to compounds to be used in a low dose in treatment of neurodegenerative diseases or disorders. It also relates to methods for treatment of a neurodegenerative diseases or disorders.... Agent: Acadia Pharmaceuticals Inc.

20140329904 - Increasing the bioavailability of hydroxycinnamic acids: The present invention generally relates to the field of nutrition, health and wellness. For example, the present invention relates to hydroxycinnamic acids and their health benefits. The present invention discloses compositions that allow increasing the bioavailability and/or bioefficacy of hydroxycinnamic acids. According to the invention, this can be achieved by... Agent:

20140329905 - Histone deacetylase 10-inhibitor co-treatment in cancer: The present invention relates to a method of identifying a subject being susceptible to a co-treatment with an histone deacetylase 10 (HDAC10)-inhibitor, said subject being in need of and/or being treated with cancer therapy against a cancer, comprising the steps of a) determining the amount of an HDAC10 gene product... Agent:

20140329906 - Thermogelling anaesthetic compositions: The present invention relates to a thermogelling pharmaceutical composition comprising local anaesthetics in base form and which is suitable for topical administration. The compositions further comprise a polyoxyethylene castor oil and one or more surfactants to obtain thermogelling characteristics.... Agent:

20140329907 - Catecholamine derivatives for obesity and neurological disorders: Novel compounds, compositions, and methods related to the activation of the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing a catecholamine backbone and pharmaceutically acceptable salts, prodrugs, and derivatives thereof. Specifically, methods, compositions, and compounds for the... Agent:

20140329908 - Method for the treatment of dravet syndrome: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at... Agent:

20140329909 - Small molecule xanthine oxidase inhibitors and methods of use: Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.... Agent:

20140329910 - Cooling agent and trpm8 activator: wherein R1 represents a hydrogen atom; R2 represents a hydrogen atom, a hydroxyl group, or an alkoxy group having from 1 to 3 carbon atoms; R3 represents a hydrogen atom or a hydroxyl group; R4 represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms, an... Agent: Kao Corporation

20140329911 - Predictive marker of dnmt1 inhibitor therapeutic efficacy and methods of using the marker: Provided herein are methods for predicting efficacy of a DNA (cytosine-5)-methyltransferase 1 (DNMT1) inhibitor treatment in a subject having a cancer, methods of identifying a subject having a cancer that is more likely to respond to a DNMT1 inhibitor treatment, and methods of selecting a treatment for a subject having... Agent: University Of Louisville Research Foundation, Inc.

20140329912 - Contraceptive compositions and methods of contraception: Compositions and methods for contraception are disclosed that use 1-bromopropane.... Agent: Integrity Pharmaceuticals, LLC

20140329913 - Nanoparticles with enhanced mucosal penetration or decreased inflammation: Nanoparticles formed by emulsion of one or more core polymers, one or more surface altering materials, and one or more low molecular weight emulsifiers have been developed. The particles are made by dissolving the one or more core polymers in an organic solvent, adding the solution of the one or... Agent: The Johns Hopkins University

20140329914 - Amphiphilic peptides for thoracic air leakage occlusion: Provided are compounds and methods useful for sealing air leaks in the thoracic cavity. Compounds and compositions of the invention comprise certain amphiphilic peptides, 8-200 amino acid residues long, that self-assemble spontaneously to form a gel in the presence of physiological pH and/or in the presence of a cation. In... Agent: 3-d Matrix Ltd.

20140329915 - Hydrogel adapted for treatment of acute dermal wounds: The present invention provides compositions and methods useful in the treatment of wounds, particularly in reducing or preventing scar formation, particularly hypertrophic scar or keloid formation. The invention thus further provides methods of treatment, including methods useful in hypertrophic scar or keloid revision as well as prophylactic, scar inhibiting methods.... Agent: Halscion, Inc.

20140329916 - Microorganisms and methods for enhancing the availability of reducing equivalents in the presence of methanol, and for producing adipate, 6-aminocaproate, hexamethylenediamine or caprolactam related thereto: Provided herein is a non-naturally occurring microbial organism having a methanol metabolic pathway that can enhance the availability of reducing equivalents in the presence of methanol. Such reducing equivalents can be used to increase the product yield of organic compounds produced by the microbial organism, such as adipate, 6-aminocaproate, hexamethylenediamine... Agent: Genomatica, Inc.

20140329917 - Apparatus, system and method for identifying circulating tumor cells: Apparatus, systems and methods are provided for the identification of various objects, particularly circulating tumor cells. In one aspect the system includes, but is not limited to, a scanning system, an image storage system, and an analysis system. The analysis system preferably identifies desired objects, such as complete cells, based... Agent:

20140329918 - Sprayhead for a spray device: A sprayhead (1) suitable for use with an aerosol container (2) comprising a central valve stem, said sprayhead (1) comprising a chassis (3) capable of firm attachment to the valve cup of an aerosol container (2), said chassis (3) comprising a circular platform (12) and a peripheral skirt (14); a... Agent:

  
  
Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141113: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 1.52514 seconds

PATENT INFO